BIOMAT Database Logo BIOMAT Database Logo

A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab. 2008

K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
Division of Endocrinology and Metabolism, Haematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Evans syndrome is a rare autoimmune disorder with unknown aetiology. Although corticosteroids and/or intravenous immunoglobulin (IVIG) are commonly used in its treatment, no standard strategy has been established. We report here a 44-year-old male with refractory Evans syndrome combined with systemic lupus erythematosus (SLE) who responded well to rituximab. He was admitted to our hospital with severe bleeding caused by worsening of Evans syndrome. Despite treatment with a high-dose corticosteroid and IVIG, his thrombocytopaenia and haemolytic anaemia did not improve. We started rituximab at a dose of 375 mg/m(2) once a week for a total of two doses. There was significant improvement in his thrombocytopaenia and anaemia 1 month after administration of rituximab. Although the total immunoglobulin G (IgG) level did not change, the titres of platelet-associated IgG (PA-IgG) and of an indirect antiglobulin test (IAT) decreased under the treatment with rituximab. It is suggested that rituximab would be a powerful candidate in the treatment of refractory Evans syndrome by depleting abnormal clone-producing autoantibody.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000305 Adrenal Cortex Hormones HORMONES produced by the ADRENAL CORTEX, including both steroid and peptide hormones. The major hormones produced are HYDROCORTISONE and ALDOSTERONE. Adrenal Cortex Hormone,Corticoid,Corticoids,Corticosteroid,Corticosteroids,Cortex Hormone, Adrenal,Hormone, Adrenal Cortex,Hormones, Adrenal Cortex
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
Bullous systemic lupus erythematosus successfully treated with rituximab.
June 2019, Cutis,
K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
Shrinking lung syndrome in systemic lupus erythematosus successfully treated with rituximab.
September 2016, QJM : monthly journal of the Association of Physicians,
K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
Myelofibrosis associated with systemic lupus erythematosus successfully treated with rituximab.
November 2019, Lupus,
K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
Colitis associated with active systemic lupus erythematosus successfully treated with rituximab.
March 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,
K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
Active systemic lupus erythematosus successfully treated with Rituximab and oral steroid.
January 2004, Clinical and experimental rheumatology,
K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
A case of systemic lupus erythematosus/systemic sclerosis overlap syndrome successfully treated with belimumab.
October 2020, European journal of dermatology : EJD,
K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
Refractory Bullous Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report and Literature Review.
January 2023, Clinical, cosmetic and investigational dermatology,
K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
Systemic lupus erythematosus combined with Evans syndrome and primary biliary cirrhosis: A rare case.
November 2023, Asian journal of surgery,
K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
Diffuse alveolar haemorrhage in a systemic lupus erythematosus patient successfully treated with rituximab: a case report.
January 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
K Kittaka, and H Dobashi, and N Baba, and K Iseki, and T Kameda, and K Susaki, and A Kitanaka, and Y Kubota, and T Ishida
Small muscle myositis in a patient with systemic lupus erythematosus successfully treated with rituximab.
October 2011, Lupus,
Copied contents to your clipboard!